News headlines about RadNet (NASDAQ:RDNT) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RadNet earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 48.3345430664572 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have effected Accern’s analysis:
- Senvest Management LLC Lowers Stake in RadNet Inc. (RDNT) (americanbankingnews.com)
- RadNet (RDNT) to Release Quarterly Earnings on Monday (americanbankingnews.com)
- Zacks Investment Research Downgrades RadNet (RDNT) to Sell (americanbankingnews.com)
- FY2018 EPS Estimates for RadNet Inc. (RDNT) Lowered by Analyst (americanbankingnews.com)
- Jefferies Group Weighs in on RadNet Inc.’s Q4 2017 Earnings (RDNT) (americanbankingnews.com)
Shares of RadNet (NASDAQ:RDNT) traded up $0.10 during mid-day trading on Monday, reaching $10.20. The company’s stock had a trading volume of 70,800 shares, compared to its average volume of 140,060. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 7.88. RadNet has a 12-month low of $5.25 and a 12-month high of $11.90. The company has a market capitalization of $485.76, a P/E ratio of 44.35, a P/E/G ratio of 2.45 and a beta of 0.67.
In other RadNet news, insider Norman R. Hames sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the sale, the insider now owns 407,257 shares in the company, valued at $4,072,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John V. Crues sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $10.08, for a total value of $201,600.00. Following the completion of the sale, the director now owns 563,781 shares of the company’s stock, valued at approximately $5,682,912.48. The disclosure for this sale can be found here. Insiders sold 73,084 shares of company stock valued at $727,787 in the last quarter. Corporate insiders own 9.36% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3223560/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-radnet-rdnt-stock-price.html.
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.